Humacyte (HUMA) director receives 80,000 stock options at $1.08 exercise price

Rhea-AI Filing Summary

Humacyte, Inc. director Michael T. Constantino received a grant of stock options covering 80,000 shares of Common Stock. The options have an exercise price of $1.08 per share and expire on June 11, 2036. The first 25% vests on June 11, 2027, with the remaining portion vesting in equal monthly installments through June 11, 2030.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Constantino Michael T.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	80,000	$0.00	--

Holdings After Transaction: Stock Options (right to buy) — 80,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 80,000 options Exercise price: $1.08 per share Expiration date: June 11, 2036 +3 more

6 metrics

Options granted 80,000 options Stock Options (right to buy) granted to director

Exercise price $1.08 per share Conversion or exercise price of options

Expiration date June 11, 2036 Option expiration for this grant

Initial vesting date June 11, 2027 First 25% of options become exercisable

Final vesting date June 11, 2030 Monthly vesting completes by this date

Shares underlying options 80,000 shares Underlying Humacyte Common Stock

Key Terms

Stock Options (right to buy), Grant, award, or other acquisition, exercise price, Common Stock, +1 more

5 terms

Stock Options (right to buy) financial

"security_title: "Stock Options (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "1.0800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"underlying_security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

derivative securities financial

"derivativeTransactionCount for derivative-type records"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Constantino Michael T.

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.08	06/11/2026		A		80,000		(1)	06/11/2036	Common Stock	80,000	$0	80,000	D

Explanation of Responses:

1. The first 25% of the option becomes exercisable on June 11, 2027, after which 1/48 of the option will become exercisable on the 11th of each month through June 11, 2030.

	/s/ Michael T. Constantino by Dale A. Sander as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Humacyte (HUMA) report in this Form 4?

Humacyte reported that director Michael T. Constantino received a grant of stock options for 80,000 shares of Common Stock. These options were awarded at an exercise price of $1.08 per share and represent a compensation-related acquisition, not an open-market share purchase or sale.

What are the key terms of Michael T. Constantino’s Humacyte (HUMA) stock options?

The grant covers 80,000 stock options with an exercise price of $1.08 per share, expiring on June 11, 2036. These options give the right to buy Humacyte Common Stock in the future, subject to the vesting schedule disclosed in the filing footnote.

How do the Humacyte (HUMA) options granted to Michael T. Constantino vest?

The first 25% of the options become exercisable on June 11, 2027. After that date, 1/48 of the total grant vests on the 11th of each month, continuing this pattern until full vesting is reached on June 11, 2030.

Is the Humacyte (HUMA) Form 4 transaction a stock purchase or sale?

The Form 4 reports an option grant, classified as a grant, award, or other acquisition. It does not show an open-market stock purchase or sale; instead, it reflects compensation-related stock options that may be exercised later at $1.08 per share.

How many Humacyte (HUMA) derivative securities does Michael T. Constantino hold after this grant?

After this transaction, Constantino holds 80,000 stock options as reported. These options are derivative securities tied to Humacyte Common Stock, and their exercisability is governed by the vesting schedule and expiration date disclosed in the Form 4.